OPRD1

OPRD1 encodes the delta (δ) opioid receptor - the Gi/o-coupled class A GPCR that mediates spinal and supraspinal analgesia, mood regulation, antidepressant-like effects, and cardioprotection through preferential activation by enkephalins. Unlike the mu receptor, delta receptor agonism produces analgesia with substantially reduced respiratory depression, addiction liability, and constipation, making OPRD1 a target for non-addictive analgesics and antidepressants. DOP/MOP heterodimers in spinal cord modulate cross-receptor desensitization. No delta-selective peptide is approved, but the receptor's clean side-effect profile continues to drive clinical-stage programs.

OPRD1 (chromosome 1p35.3, ~372 aa) adopts the canonical class A GPCR fold. Endogenous ligands: [Met⁵]-enkephalin (Tyr-Gly-Gly-Phe-Met) and [Leu⁵]-enkephalin bind with Ki ~1–4 nM; δ-endorphin; dermorphin-related peptides at moderate affinity. Synthetic reference agonists: DPDPE (cyclic, δ-selective, Ki ~2 nM), SNC80 (non-peptide, Ki ~4 nM), ARM390. Crystal structure of DOP with naltrindole (PDB: 4EJ4) defined the selectivity-determining pocket: a wider, more open binding cavity compared to MOP, shaped by ECL2 and TM6/TM7 differences. The N-terminal Tyr of enkephalins is critical - its removal or D-substitution abolishes activity. Signaling: Gi/o → ↓cAMP → ↓PKA; GIRK channel opening → hyperpolarization; N/P/Q-type Ca²⁺ channel closure → ↓ neurotransmitter release; β-arrestin-2 → MAPK/ERK (biased component). MOP/DOP heterodimers show altered pharmacology: DOP activation in MOP-DOP heteromers promotes MOP internalization and counteracts MOP tolerance development. OPRD1 is richest in olfactory bulb, neocortex, amygdala, hippocampus, and spinal dorsal horn laminae I/II; also in GI tract and cardiac myocytes (cardioprotection against ischemia/reperfusion injury through δ receptor preconditioning).

No delta-selective opioid is FDA-approved. Naltrindole (NTI) is the selective delta antagonist research standard. Deltorphin II (Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH₂, from Phyllomedusa skin) is a highly potent, selective OPRD1 agonist (Ki ~0.5 nM) widely used as a pharmacological probe. SNC80 showed antidepressant and anxiolytic effects in rodents but caused convulsions in early studies, driving development of biased analogs. For peptide research, the tractable recipes are: Tyr¹-Gly²-Gly³-Phe⁴ enkephalin N-terminal scanning with D-amino acids at positions 2 or 4 (e.g., DADLE: Tyr-D-Ala-Gly-Phe-D-Leu) for protease resistance without receptor bias shift; cyclic enkephalin analogs with Cys4–Cys7 or side-chain lactam constraints (DPDPE template) for δ over μ selectivity; biased DOP agonists favoring Gi over β-arrestin-2 to preserve antidepressant/analgesic activity without convulsive potential; and bivalent MOP/DOP ligand scaffolds that simultaneously engage both receptors to suppress MOP tolerance while maintaining adequate analgesia for chronic pain indications.